This is interesting: Mr. Moscato will discuss a
Post# of 36537
(Total Views: 342)
Posted On: 03/31/2021 11:09:38 AM
This is interesting:
Mr. Moscato will discuss advancements regarding its FDA IND submission where Generex has surpassed the final threshold and has completed its GMP manufacturing of its vaccine for human clinical trials, which is a key necessary component to be included in the company’s IND submission. He will further elaborate on our Ii-Key COVID-19 Complete Vaccine, including progress being made and steps taken with our Malaysia and China partnerships. Mr. Moscato will also update shareholders on the status of the company’s submitted application for listing NuGenerex Immuno-Oncology (NGIO) on the NASDAQ stock market.
So, will they be submitting the IND in the next week maybe or have they already?
Mr. Moscato will discuss advancements regarding its FDA IND submission where Generex has surpassed the final threshold and has completed its GMP manufacturing of its vaccine for human clinical trials, which is a key necessary component to be included in the company’s IND submission. He will further elaborate on our Ii-Key COVID-19 Complete Vaccine, including progress being made and steps taken with our Malaysia and China partnerships. Mr. Moscato will also update shareholders on the status of the company’s submitted application for listing NuGenerex Immuno-Oncology (NGIO) on the NASDAQ stock market.
So, will they be submitting the IND in the next week maybe or have they already?
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼